InMed Pharmaceuticals Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)
For the Three and Nine Months ended March 31, 2025 and 2024
| Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total | ||||||
|---|---|---|---|---|---|---|
| # | $ | $ | $ | $ | $ | |
| Balance July 1, 2024 | 445,908 | 82,784,400 | 35,368,899 | (109,075,759) | 128,569 | 9,206,109 |
| Private placement | 186,361 | 1,030,063 | - | - | - | 1,030,063 |
| Share issuance costs | - | (191,824) | - | - | - | (191,824) |
| Exercise of pre-funded warrants | 34,700 | 576,034 | (576,034) | - | - | - |
| Loss for the period | - | - | - | (1,677,868) | - | (1,677,868) |
| Share-based compensation | - | - | 28,964 | - | - | 28,964 |
| Balance September 30, 2024 | 666,969 | 84,198,673 | 34,821,829 | (110,753,627) | 128,569 | 8,395,444 |
| Private Placement | 57,183 | 396,153 | - | - | - | 396,153 |
| Share issuance costs | - | (57,632) | - | - | - | (57,632) |
| Loss for the period | - | - | - | (2,575,024) | - | (2,575,024) |
| Share-based compensation | - | - | 23,159 | - | - | 23,159 |
| Balance December 31, 2024 | 724,152 | 84,537,194 | 34,844,988 | (113,328,651) | 128,569 | 6,182,100 |
| Private Placement | 483,034 | 2,935,004 | - | - | - | 2,935,004 |
| Share issuance costs | - | (15,103) | - | - | - | (15,103) |
| Loss for the period | - | - | - | (2,120,930) | - | (2,120,930) |
| Share-based compensation | - | - | 40,454 | - | - | 40,454 |
| Balance March 31, 2025 | 1,207,186 | 87,457,095 | 34,885,442 | (115,449,581) | 128,569 | 7,021,525 |
| Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total | ||||||
|---|---|---|---|---|---|---|
| # | $ | $ | $ | $ | $ | |
| Balance July 1, 2023 | 166,410 | 77,620,252 | 35,741,115 | (101,400,209) | 128,569 | 12,089,727 |
| Net loss | - | - | - | (2,536,828) | - | (2,536,828) |
| Share-based compensation | - | - | 25,191 | - | - | 25,191 |
| Balance September 30, 2023 | 166,410 | 77,620,252 | 35,766,306 | (103,937,037) | 128,569 | (9,578,090) |
| Private placement | 116,989 | 2,316,381 | 2,899,812 | - | - | 5,216,193 |
| Share issuance costs | - | - | (562,151) | - | - | (562,151) |
| Loss for the period | - | - | - | (1,478,185) | - | (1,478,185) |
| Share-based compensation | - | - | 18,264 | - | - | 18,264 |
| Balance December 31, 2023 | 283,399 | 79,936,633 | 38,122,231 | (105,415,222) | 128,569 | 12,772,211 |
| Private placement | 33,850 | 670,230 | (670,230) | - | - | - |
| Loss for the period | - | - | (1,722,866) | - | (1,722,866) | |
| Share-based compensation | - | - | 55,305 | - | - | 55,305 |
| Balance March 31, 2024 | 317,249 | 80,606,863 | 37,507,306 | (107,138,088) | 128,569 | 11,104,650 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.